Aprea Therapeutics, Inc. — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On July 23, 2026, Aprea Therapeutics, Inc. filed an 8-K reporting Item 3.01 — Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. The filing does not provide specific details of the delisting trigger, listing standard violated, or timeline for potential transfer or delisting action. For a company with ~$8.6M market value, delisting represents an existential threat to public market access and liquidity.
Why this rating
Delisting notice is business-threatening for a micro-cap; threatens financing, liquidity, and shareholder value fundamentally.
Extracted items
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.